Sentences with phrase «cell precursor acute»

Other CAR T - cell therapies approved in 2017 include tisagenlecleucel for the treatment of children and young adults up to 25 years of age with relapsed or refractory B - cell precursor acute lymphoblastic leukemia and axicabtagene ciloleucil (aci - cel; Yescarta) for adults with relapsed or refractory DLBCL.

The genetic basis of early T - cell precursor acute lymphoblastic leukaemia Nature, 481 (7380), 157 - 163 DOI: 10.1038 / nature10725

In 2014, the FDA approved Amgen's BLINCYTO ® (blinatumumab), the first BiTE ® therapy to receive FDA approval, for the treatment of Philadelphia chromosome - negative relapsed or refractory B - cell precursor acute lymphoblastic leukemia, a rare and rapidly progressing cancer of the blood and bone marrow.

The drug, which was first approved last August for patients under 25 with B - cell precursor acute lymphoblastic leukemia, is now OK» ed to treat large B - cell lymphoma.

In March, the U.S. Food and Drug Administration (FDA) approved BLINCYTO for the treatment of adults and children with B - cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percent.

Not exact matches

In PLAT - 02, the CAR T cells are reprogrammed to recognize and target the CD19 protein that is expressed by most precursor B acute lymphoblastic leukemia cells.

Effects of the chemokine stromal cell - derived factor - 1 on the migration and localization of precursor - B acute lymphoblastic leukemia cells within bone marrow stromal layers.

Consistent with prior reports on effector cells (35), we observed that, among CD8 + T cells specific for the dominant epitope of LCMV (GP33), the percentages of short - lived effector cells (KLRG1 + CD127 −) were increased, and the percentages of memory precursor cells (KLRG1 + CD127 +) were decreased in the peripheral blood of DGKζ − / −, Cbl - b − / −, and DKO mice relative to WT mice after acute infection (Fig. 5A).

A phase I / II trial of KTE - C19 (anti-CD19 CAR T cells) for pediatric and adolescent subjects with relapsed / refractory B - precursor acute lymphoblastic leukemia -LRB-

CpG stimulation of precursor B lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells towards a Th1 response.

IL - 6 has been shown to be involved in diverse physiological processes such as T - cell activation, induction of immunoglobulin secretion, initiation of hepatic acute phase protein synthesis, and stimulation of hematopoietic precursor cell proliferation and differentiation.